Our study reveals differences in the clinical characteristics of patients with different molecular subtypes, with a higher proportion of women with TN status and HER-2+ having larger tumor size, advanced stage at diagnosis and lymph node metastasis. The gene discussed is ERBB2; the disease is metastatic malignant neoplasm in the lymph nodes.